Hunterbrook Capital long Bioage Labs, Hunterbrook Media reports

Following the “catastrophic failure of its sole clinical program,” BioAge Labs (BIOA) fell to around $150M market cap, despite over $300M in cash and a potentially valuable preclinical asset, stated Hunterbrook Media’s Nathaniel Horwitz in a report that also discloses that Hunterbrook Capital is long Bioage based on Hunterbrook Media’s reporting. The report adds: “That new lead program is a drug for the inflammation protein NLRP3, a popular target: Analogous NLRP3 programs have scored deals worth hundreds of millions from pharma giants Novartis (NVS) and Novo Nordisk (NVO) to treat a wide range of inflammatory diseases… This week, BioAge announced a partnership with Novartis for other programs to target age-related diseases, building on BioAge’s founding mission to fight aging. The deal includes a $20 million upfront payment and up to $530 million in future payments… The day before the partnership, $BIOA had traded under $4, with about $10 in cash per share… But now, with the Novartis partnership and a massive war chest, could BioAge live a second life with its new lead program?”